Table 1.

Clinical benefits of ART in patients with head and neck cancer.

	Nb patients				Replanning strategies			Clinical endpoint
Author (year)	ART	No ART	Tumor site	Total dose (Gy)	Nb	Timing	Follow-up (months)	Loco-regional control and survival	Acute toxicity	Late toxicity
Schwartz (2012) (10)^a	22	0	OPC	66–70	1 or 2	16^th and 22^th fr	31	2-year LRC = 95%	G III mucosal = 100% G II xerostomia = 55% G III xerostomia = 5%	Full preservation or functional recovery of speech and eating at 20 months
Kataria (2016) (66)	36	0	LAHNC	70	1	54 Gy		2-year DFS = 72% 2-year OS = 75%	G II-III mucosal = 100%	G II xerostomia= 8% G II mucosal = 11% No G III
Yang (2013)^a(67)	86	43	NPC	70–76	1 or 2	15^th and/or 25^th fr	29	2-year LRC 97.2% (ART) 82.2% (no-ART) p = .04 2-year OS 89.8% (ART) 82.2% (No-ART) p = .47		Improvements in quality of life with ART
Chen (2014)(68)	51	266	LAHNC	60^b 70^μ	1	40 Gy (10–58Gy)	30	2-year LRC 88% (ART) 79% (No-ART) p = .01 2-year OS 73% (ART) 79% (No-ART) p = .55	G III: 39% (ART) 30% (No-ART) p = .45	G III: 14% (ART) 19% (No-ART) p = .71
Zhao (2011)(69)	33	66	NPC	70	1	15^th (+/−5) fr	38	3-year LRFS 72.7% (ART) 68.1% (No-ART) p = .3		No difference except less xerostomia and mucosal with ART for N2 and N3 patients

prospective studies (non-randomized)

= Adjuvant RT

^μ

= Definitive RT

Nb pts: number of patients; LAHNC: locally advanced head and neck cancer; OPC: oropharynx cancer; NPC: nasopharyngeal carcinoma; Nb: number; ART: adaptive radiotherapy; Fr: fraction; LRC: loco-regional control; LRFS: loco-regional free survival; DFS: disease-free survival; OS: overall survival